Lung cancer (unresectable stage III) study

Full Name

Lung Cancer (E6508): A phase II study of L-BLP25 and bevacizumab in unresectable stage IIIA and IIIB non-squamous non-small cell lung cancer after definitive chemoradiation (2_PRO00000270)

Description

Participants will receive radiation therapy five days per week and weekly chemotherapy with paclitaxel and carboplatin for 6ï¿½ weeks. Disease is then evaluated; if complete or partial response, or stable disease, participant then receives consolidation chemotherapy (paclitaxel and carboplatin every 3 weeks for 2 doses). Disease is once again evaluated. Again, if there is complete or partial response, or stable disease, participant is registered into maintenance therapy, which consists of cyclophosphamide (given once), bevacizumab (every 3 weeks for 24 months), and L-BLP25 vaccine (given by injection weekly for 6 weeks and then once every 6 weeks for 24 months). Participants can continue on study for the full 27 months unless there is progression of disease.

Eligibility

Inclusion Criteria

Newly diagnosed, histologically confirmed non-squamous non-small cell lung cancer
Appropriate stage of disease
Appropriate performance scores
At least 18 years of age
Adequate organ function
Must not have had prior chemotherapy for lung cancer
Cannot be pregnant or breastfeeding; must agree to a pregnancy test
Must agree to use an accepted and effective method of contraception during study treatment and for at least 6 months after completion of bevacizumab